GPC3 and hepatocellular carcinoma: They made efforts to design and construct two recombinant ITs against HCC cells, including a modified truncation of Pseudomonas exotoxin A (mPE24) and HN3 human single-domain VH as the targeting anti-GPC3 antibody in one and two repeats (HN3-mPE24 and HN3-HN3-mPE24).